A Multiple‐Ascending‐Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK‐875, in Subjects With Type 2 Diabetes
暂无分享,去创建一个
H. Naik | M. Vakilynejad | M. Kipnes | D. Demanno | P. Viswanathan | E. Leifke | J. Wu | E. Leifke